Q2 2025 VolitionRX Ltd Earnings Call Transcript
Key Points
- VolitionRX Ltd (VNRX) achieved a 15% increase in total revenue for the first half of 2025, with the first revenue recorded from sales of a human product, Nu.Q NET.
- The company successfully reduced total operating expenses by 22% and net cash used in operating activities by 30% compared to the previous year.
- VolitionRX Ltd (VNRX) is in active negotiations with over 10 companies for potential licensing agreements, with some discussions at the contract finalization stage.
- The Nu.Q platform has shown promising results in various clinical studies, including its use as a prognostic marker in non-small cell lung cancer and as a biomarker for sepsis.
- The company recorded its first revenue from sales of the CE Mark Nu.Q NETs automated product in Europe, with 11 hospital networks in five countries placing orders.
- Revenues remain unpredictable and 'lumpy' at this early stage of commercialization, leading to a lack of revenue guidance for 2025.
- Cash and cash equivalents decreased to approximately $2.3 million at the end of the quarter, down from $3.3 million at the end of 2024.
- The company is dependent on executing licensing agreements with significant upfront payments to achieve its goal of being cash neutral for the year.
- The commercialization of the Nu.Q platform in the human diagnostic market is still in progress, with no finalized out-licensing deals yet.
- The regulatory path for some products, such as those requiring FDA approval, could take 2 to 3 years, delaying potential revenue streams.
Good morning, ladies and gentlemen, and thank you for standing by. Welcome to VolitionRx Limited second-quarter 2025 earnings conference call. (Operator Instructions)
This conference is being recorded today, August 15, 2025. I'd now like to turn the call over to Louise Batchelor, Group Chief Marketing and Communications Officer. Please go ahead.
Thank you, and welcome, everyone, to today's earnings conference call for VolitionRx Limited. Before we begin, I'd like to remind everyone that some of the information discussed on this conference call will include forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
These statements are based on our beliefs, as well as assumptions we have used, based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties and assumptions. Actual future
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
